skip to Main Content

Study Establishes New Standard of Care for Pancreatic Cancer Patients

Newsfeed image, light gray text on dark gray background
A combination of two chemotherapy drugs – gemcitabine and capecitabine – should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumour, according to a Cancer Research UK-funded study published in The Lancet.

“This is one of the biggest ever breakthroughs prolonging survival for pancreatic cancer patients.” – Professor John Neoptolemos

Experts say the combination should replace the standard treatment of giving patients gemcitabine alone following surgery. Read more . . .

Back To Top